Navigating Post-Brexit UK QPPV & MHRA Inspection Readiness: The Senior Pharmacovigilance Playbook

1. The Post-Brexit UK QPPV Mandate: Beyond "Paper Compliance"

Under UK law, every MAH holding a marketing authorisation in Great Britain (England, Scotland, and Wales) must establish and maintain a dedicated Qualified Person for Pharmacovigilance who resides and operates within the United Kingdom. While the MHRA permitted a temporary 21-month procedural derogation immediately post-transition, that flexibility has fully expired.

MHRA inspectors routinely issue Major Findings when biotech and international pharmaceutical sponsors designate a nominal UK QPPV who lacks 24/7 direct access to the global safety database, signal detection meetings, and product change controls. The UK QPPV cannot simply be a "rubber stamp"—they carry personal, statutory accountability under Regulation 182 of SI 2012/1916 for the overall safety profile of products marketed in Great Britain.

2. The Pharmacovigilance System Master File (PSMF): Structure & Living Version Control

The UK PSMF is the foundational legal document requested by MHRA inspectors with as little as 7 calendar days' notice prior to routine or unannounced GPvP inspections. According to the MHRA's recent GPvP inspection metric reports, over 78% of critical and major findings originate from deficient, outdated, or internally inconsistent PSMF documentation.

A compliant UK PSMF requires rigorous maintenance of critical annexes:

• Annex A (Qualified Person): Complete curriculum vitae, job description, 24/7 emergency contact details, back-up QPPV arrangements, and signed delegation protocols.
• Annex B (Organisational Structure): Global vs UK organizational charts, lists of contractual safety data exchange agreements (SDEAs), and third-party vendor audit trails.
• Annex C (Sources of Safety Data): Verified lists of worldwide spontaneous sources, clinical trials, post-authorisation safety studies (PASS), and compassionate use programs.
• Annex G (Continuous Logbook): Chronological record of all alterations made to the pharmacovigilance system over the preceding 5 years, with documented justification and management approvals.

3. Strategic Delivery Model Comparison: CRO vs In-House vs Director-Led

Biotechnology sponsors and emerging pharmaceutical companies face a critical architectural decision when resourcing their UK pharmacovigilance framework. The table below illustrates the operational tradeoffs across models:

4. Signal Detection, PBRERs & Risk Management Plans (RMPs)

Modern pharmacovigilance is not merely reactive case handling—it is predictive clinical intelligence. The MHRA expects MAHs to conduct systematic monthly statistical signal evaluations (using disproportionality metrics such as PRR and ROR) coupled with physician-led qualitative validation.

Furthermore, preparing periodic benefit-risk evaluation reports (PBRERs/PSURs) requires cross-functional alignment between safety data scientists, clinical pharmacologists, and regulatory strategists. Outdated or superficial Risk Management Plans (RMPs) fail the MHRA's safety specification requirements, resulting in formal requests for corrective action (CAPA) or commercial restriction.

5. Actionable MHRA Inspection Readiness Checklist

Prior to undergoing your next MHRA GPvP surveillance audit, verify that your compliance framework satisfies these five critical milestones:

1. UK QPPV Formal Access Audit: Ensure written, tested evidence that the UK QPPV can query, extract, and review ICSR database records within 2 hours of notification.
2. PSMF Annex Reconciliation: Verify that Annex C (study protocols) and Annex B (SDEAs) match current contractual relationships without orphaned agreements.
3. Signal Meeting Audit Trails: Document formal monthly signal committee minutes, including negative signals where no action was warranted.
4. CAPA Closure Verification: Ensure all previous audit findings have documented root-cause investigations and validated closure evidence.
5. 24/7 Emergency Simulation: Conduct an unannounced mock contact drill to verify that MHRA emergency lines reach designated senior personnel immediately.